ES3061771T3 - Preparation of preliposomal annamycin lyophilizate - Google Patents

Preparation of preliposomal annamycin lyophilizate

Info

Publication number
ES3061771T3
ES3061771T3 ES20830959T ES20830959T ES3061771T3 ES 3061771 T3 ES3061771 T3 ES 3061771T3 ES 20830959 T ES20830959 T ES 20830959T ES 20830959 T ES20830959 T ES 20830959T ES 3061771 T3 ES3061771 T3 ES 3061771T3
Authority
ES
Spain
Prior art keywords
preliposomal
annamycin
lyophilizate
preparation
preliposomal annamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20830959T
Other languages
English (en)
Inventor
Donald Picker
Waldemar Priebe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Moleculin Biotech Inc
Original Assignee
University of Texas System
University of Texas at Austin
Moleculin Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, Moleculin Biotech Inc filed Critical University of Texas System
Application granted granted Critical
Publication of ES3061771T3 publication Critical patent/ES3061771T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES20830959T 2019-06-28 2020-06-25 Preparation of preliposomal annamycin lyophilizate Active ES3061771T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962868184P 2019-06-28 2019-06-28
PCT/US2020/039620 WO2020264160A1 (en) 2019-06-28 2020-06-25 Preparation of preliposomal annamycin lyophilizate

Publications (1)

Publication Number Publication Date
ES3061771T3 true ES3061771T3 (en) 2026-04-07

Family

ID=74061071

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20830959T Active ES3061771T3 (en) 2019-06-28 2020-06-25 Preparation of preliposomal annamycin lyophilizate

Country Status (14)

Country Link
US (2) US12257261B2 (es)
EP (1) EP3989978B1 (es)
JP (1) JP7687969B2 (es)
KR (1) KR20220027969A (es)
CN (1) CN114641296B (es)
AU (1) AU2024203598B2 (es)
BR (1) BR112021026506A2 (es)
EA (1) EA202193193A1 (es)
ES (1) ES3061771T3 (es)
IL (1) IL289432B1 (es)
MX (1) MX2021015668A (es)
SG (1) SG11202113009PA (es)
TW (2) TW202114703A (es)
WO (1) WO2020264160A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3049663T3 (en) 2019-06-28 2025-12-17 Univ Texas Method of reconstituting liposomal annamycin
KR20220027969A (ko) 2019-06-28 2022-03-08 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 프리리포솜 아나마이신 동결건조물의 제조
KR20220103992A (ko) * 2019-11-21 2022-07-25 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 리포솜 아나마이신에 의한 폐 표적화 항암 요법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1985A (en) 1841-02-18 Charles m
US977327A (en) 1910-06-02 1910-11-29 James Ratcliffe Device for polishing stones.
US4537882A (en) 1984-05-10 1985-08-27 Ohio State University 4-Demethoxy-3'-desamino-2'-halo-anthracycline and pharmaceutical composition containing same
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4863739A (en) 1987-05-19 1989-09-05 Board Of Regents, The University Of Texas System Liposome compositions of anthracycline derivatives
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
WO2001032145A1 (en) * 1999-10-29 2001-05-10 Board Of Regents, The University Of Texas System Method of cancer treatment
EP2314285B2 (en) 2003-02-14 2019-09-18 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
JP5917789B2 (ja) 2006-10-10 2016-05-18 ジャイナ ファーマシューティカルズ，インコーポレーテッド 脂質ベースの医薬化合物の製造のための水性系、その組成物、方法、および使用
WO2013055874A2 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
US8926994B2 (en) * 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
WO2018048752A1 (en) 2016-09-09 2018-03-15 Irisys, Inc. Lipsomal anticancer compositions
ES3049663T3 (en) 2019-06-28 2025-12-17 Univ Texas Method of reconstituting liposomal annamycin
KR20220027969A (ko) 2019-06-28 2022-03-08 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 프리리포솜 아나마이신 동결건조물의 제조
KR20220103992A (ko) 2019-11-21 2022-07-25 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 리포솜 아나마이신에 의한 폐 표적화 항암 요법

Also Published As

Publication number Publication date
US20240041909A1 (en) 2024-02-08
MX2021015668A (es) 2022-04-18
TW202114703A (zh) 2021-04-16
AU2024203598B2 (en) 2025-06-05
AU2020303572A1 (en) 2022-01-20
CN114641296A (zh) 2022-06-17
BR112021026506A2 (pt) 2022-02-15
IL289432B1 (en) 2026-04-01
EA202193193A1 (ru) 2022-03-30
US12257261B2 (en) 2025-03-25
EP3989978A1 (en) 2022-05-04
WO2020264160A1 (en) 2020-12-30
CA3142510A1 (en) 2020-12-30
US20220105115A1 (en) 2022-04-07
TWI872002B (zh) 2025-02-01
EP3989978B1 (en) 2025-12-17
SG11202113009PA (en) 2021-12-30
JP7687969B2 (ja) 2025-06-03
JP2022538865A (ja) 2022-09-06
AU2024203598A1 (en) 2024-06-20
TW202448481A (zh) 2024-12-16
EP3989978A4 (en) 2023-05-10
KR20220027969A (ko) 2022-03-08
IL289432A (en) 2022-02-01
CN114641296B (zh) 2025-05-27
US11951118B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
GB2588505B (en) Preparation of psilocybin
EP4041386A4 (en) WET PREPARATION OF RADIOTHERAPY SOURCES
GB202106894D0 (en) Process for the preparation of 3alpha-hydroxy-5#LPHA-Pregnan-20-one (brexanolone)
EP4069086A4 (en) IMAGING METHODS USING MULTIPLE IMAGING AGENTS
IL256948B (en) Estimate tissue thickness
ES3061771T3 (en) Preparation of preliposomal annamycin lyophilizate
IL289904B1 (en) Process for preparing biphenylamines
GB201906176D0 (en) Gating of radiotherepy
ZA202105399B (en) Use of spiropidion
IL288083A (en) External preparation
IL276107A (en) Crystalline forms of psoorstam
SG11202107366QA (en) Actuation of execution units
GB2575067B (en) Selection of identifiers
IL287507A (en) Methods for preparing jasmonate compounds
HK40073245A (zh) 制备安那霉素脂质体前体冻干物
SG11202105136WA (en) Application of chidamide
GB201912411D0 (en) Crystalline forms of ivosidenib
GB201910665D0 (en) Novel form of compounds
PT3868366T (pt) Preparação sólida revestida
HK40051691A (en) Preparation of psilocybin
HK40051691B (en) Preparation of psilocybin
GB201910250D0 (en) Preparation of antibacterial compounds
GB201907732D0 (en) Preparation of antibacterial compounds
ZA202109575B (en) Forming of disinfectant solutions
GB201915908D0 (en) Crystalline forms of entrectinib